Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following
direct‐acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete …

The real‐world virological efficacy and safety of interferon‐free direct‐acting antiviral (DAA)
therapy with sofosbuvir (SOF) and velpatasvir (VEL) were assessed in hepatitis C virus …

Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which
is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or …

Background Chronic hepatitis C virus therapy in patients with advanced liver disease
remains a clinical challenge. HCV‐TARGET collects data in patients treated at tertiary …

Few studies are available on metabolic changes in liver injuries and this is the first
metabolomic study evaluating a group of HCV-positive patients, before and after viral …

Fibrosis progression is common in hepatitis C. Both host and viral factors influence its
natural history. Liver fibrosis is a key predictive factor for advanced disease including …

While for many years investigators had worked on highly effective direct-acting antiviral
agent (DAA) therapy, we are now encountering challenges on the appropriate timing of DAA …

Summary The Asia-Pacific region has disparate hepatitis C virus (HCV) epidemiology, with
prevalence ranging from 0· 1% to 4· 7%, and a unique genotype distribution. Genotype 1b …

Background & Aims Direct-acting antivirals (DAAs) are effective in the treatment of chronic
hepatitis C virus (HCV) infection, although results for patients infected with genotype 3 are …

We evaluated whether indications for liver transplantation (LT) have changed among people
with/without human immunodeficiency virus (HIV) infection and compared LT outcomes and …